ATE486962T1 - Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon - Google Patents

Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon

Info

Publication number
ATE486962T1
ATE486962T1 AT05737007T AT05737007T ATE486962T1 AT E486962 T1 ATE486962 T1 AT E486962T1 AT 05737007 T AT05737007 T AT 05737007T AT 05737007 T AT05737007 T AT 05737007T AT E486962 T1 ATE486962 T1 AT E486962T1
Authority
AT
Austria
Prior art keywords
protein
receptor protein
salt
screening
new ligand
Prior art date
Application number
AT05737007T
Other languages
English (en)
Inventor
Ryo Fujii
Masataka Harada
Shuji Hinuma
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE486962T1 publication Critical patent/ATE486962T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
AT05737007T 2004-04-27 2005-04-26 Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon ATE486962T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004131726 2004-04-27
PCT/JP2005/008403 WO2005103291A1 (ja) 2004-04-27 2005-04-26 Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途

Publications (1)

Publication Number Publication Date
ATE486962T1 true ATE486962T1 (de) 2010-11-15

Family

ID=35196997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05737007T ATE486962T1 (de) 2004-04-27 2005-04-26 Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon

Country Status (6)

Country Link
US (1) US7833722B2 (de)
EP (1) EP1741792B1 (de)
JP (1) JP4685767B2 (de)
AT (1) ATE486962T1 (de)
DE (1) DE602005024537D1 (de)
WO (1) WO2005103291A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック, インコーポレイテッド 軸索変性の調節
US8460862B2 (en) * 2009-03-11 2013-06-11 Marker Gene Technologies Enzyme substrates for visualizing acidic organelles
EP2567698B1 (de) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR-17-Agonisten und Screening-Assay
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ucb製藥有限公司 吡啶基及吡基-(氮)吲哚磺醯胺
EP3584244A1 (de) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituierte alkoxypyridinylindolsulfonamide
WO2020254289A1 (en) 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
GB2701173A (en) 2024-05-23 2026-04-22 Pheno Therapeutics Ltd Compounds
GB2642355A (en) 2024-07-05 2026-01-07 Pheno Therapeutics Ltd Polymorphs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118372T3 (es) 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
GB0003902D0 (en) 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
AU2001244205A1 (en) 2000-03-14 2001-09-24 Bayer Aktiengesellschaft Regulation of human p2y-like gpcr protein
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20050118639A1 (en) 2002-02-22 2005-06-02 Takeda Chemical Industries, Ltd Method of determining ligand
US20040176344A1 (en) * 2004-04-06 2004-09-09 Rooney Roberta Nora Malone Method to treat patients with amyotrophic lateral sclerosis and the like

Also Published As

Publication number Publication date
WO2005103291A1 (ja) 2005-11-03
DE602005024537D1 (de) 2010-12-16
EP1741792B1 (de) 2010-11-03
JPWO2005103291A1 (ja) 2008-03-13
EP1741792A1 (de) 2007-01-10
JP4685767B2 (ja) 2011-05-18
US7833722B2 (en) 2010-11-16
EP1741792A4 (de) 2008-11-05
US20080248041A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
EP1479768A4 (de) Neues screening-verfahren
ATE486962T1 (de) Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
TW200531692A (en) Aryl aniline derivatives as β2 adrenergic receptor agonists
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
ATE446294T1 (de) N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
EA200600049A1 (ru) Способы получения 3 - бензазепинов
MA29088B1 (fr) Composes d'indazole-carboxamide.
BR0207390A (pt) Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
DE60312474D1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
WO2005000875A3 (en) Compositions and methods comprising a ligand of chemerin receptor
BRPI0409562A (pt) tratamento de condições envolvendo placas amilóides
FR2888937B1 (fr) Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
EP1619499A4 (de) Neues screening-verfahren
ATE482931T1 (de) Somatostatinrezeptor-1- und/oder -4-selektive agonisten und antagonisten
EP1584925A4 (de) Neues screening-verfahren
ATE405827T1 (de) Screening-verfahren
WO2003082320A1 (fr) Nouveau procede de criblage
EP1617216A4 (de) Neues screening-verfahren
WO2004096855A3 (en) Methods utilising g-protein coupled receptor 54
ATE447586T1 (de) Fprl1-liganden und deren verwendung
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
SE0101856D0 (sv) Galanin receptor agonist
WO2007044940A3 (en) Antibody against a peptide derived from human mutant lamin a protein and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties